Gilead Sciences, Inc. vs Vale SA — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Vale SA trades at $14.39 (market cap $62.26B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× Vale SA's market cap, and Vale SA pays the higher dividend (8.12%). Which is the better fit depends on your goals.
| GILD | VALE | |
|---|---|---|
Market Cap | $164.99B | $62.26B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $17.82 |
52-Week Low | $110.56 | $9.71 |
Enterprise Value | $188.06B | $78.50B |
Dividend Yield | 2.47% | 8.12% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →